Needham & Company
View Older Stories
-
Needham & Company Reiterates Strong Buy on MiMedx Group (MDXG) Following 2Q Results
-
MiMedx Group (MDXG) PT Raised to $20 at Needham & Company; 'We Expect Wound RCTs to Drive Increased EpiFix Coverage and Adoption'
-
Needham Comments On MiMedx Group (MDXG): Co. Will Maintain Leadership In The Skin Substitute Market
-
MiMedx Group (MDXG) PT Raised to $15 at Needham & Company on 1Q Pre-Announce Revenue Beat
-
MiMedx To Present At The 16th Annual Needham Healthcare Conference
-
Needham & Company Reiterates Strong Buy on MiMedx Group (MDXG) Following 2017 Guide
-
ResMed (RMD), St. Jude (STJ), Cepheid (CPHD) Among Med Tech Companies with Most EU Exposure - Needham & Company
-
Needham & Company Cuts Price Target as MiMedx Group (MDXG) Preannounces 1Q Revenue Miss
-
MiMedx To Present At The 15th Annual Needham Healthcare Conference
-
Needham & Company Upgrades MiMedx Group (MDXG) to Strong Buy
-
Needham & Company Cuts Price Target on MiMedx Group (MDXG) Following Analyst Day
-
Needham & Company Reiterates Buy on MiMedx Group (MDXG) Ahead of Growth Opportunities
-
Needham & Company Downgrades MiMedx Group (MDXG) to Buy
-
MiMedx To Present At The 14th Annual Needham Healthcare Conference
-
MiMedx Group (MDXG) PT Raised to $15 at Needham & Company as Momentum Continues
-
Notable Analyst Rating Changes 2/20: (MRVL) (DSW) (KN) Upgraded; (FUEL) (HLSS) (REGN) Downgraded
-
Needham & Company Upgrades MiMedx Group (MDXG) to Strong Buy
-
MiMedx Group (MDXG) Buy Rating Maintained at Needham
-
Streetinsider.com's Hot Lunchtime Reads 12/31: (TWTR) (CAT) (UST) (MDXG)
-
MiMedx (MDXG) Could See Additional Revenue Upside if FDA Agrees to Temp. Micronized Product Sales - Needham & Co.
-
MiMedx Group (MDXG) PT Raised to $13 at Needham & Company Following Updated 2015 Guidance
-
MiMedx Group (MDXG) PT Raised to $12 at Needham & Company on EpiFix Results
-
Needham & Company Starts MiMedx Group (MDXG) at Buy